Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Daxor Corp (DXR)

Daxor Corp (DXR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,696
  • Shares Outstanding, K 4,034
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -7,190 K
  • 60-Month Beta -1.09
  • Price/Sales 37.91
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade DXR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.99 +18.35%
on 08/24/21
12.24 -13.07%
on 09/14/21
+1.49 (+16.29%)
since 08/20/21
3-Month
8.62 +23.44%
on 07/29/21
13.55 -21.48%
on 07/22/21
+0.10 (+0.98%)
since 06/22/21
52-Week
8.58 +24.01%
on 05/17/21
17.58 -39.48%
on 02/05/21
-4.09 (-27.77%)
since 09/22/20

Most Recent Stories

More News
Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021

Company forecasts further increase in sales driven by new distributor agreements

DXR : 10.64 (-3.97%)
Dynamic Funds announces August 2021 cash distributions for Dynamic Active ETFs

COMTEX_391844640/2669/2021-08-19T09:00:41

DXR : 10.64 (-3.97%)
Daxor's Blood Volume (BVA-100(R)) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

Data Led to Multi-Center Study In Progress At Three Leading Hospitals

DXR : 10.64 (-3.97%)
DAXOR CORPORATION ANNOUNCES NON-GOVERNMENT DISTRIBUTION AGREEMENT WITH CONCORDANCE(R) HEALTHCARE SOLUTIONS

Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has signed a non-government distribution agreement with Concordance Healthcare Solutions,...

DXR : 10.64 (-3.97%)
American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

Cites Evidence from Studies Utilizing Daxor's BVA-100 Blood Volume Analyzer

DXR : 10.64 (-3.97%)
Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021

DaxorCorporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that Michael Feldschuh, Daxor's President and Chief Executive Officer will present at the Summer...

DXR : 10.64 (-3.97%)
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021

The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor...

RDHL : 4.75 (-1.25%)
PHO : 56.64 (+0.73%)
ECOR : 0.9700 (+1.58%)
MKTY : 8.22 (+3.53%)
SLNG : 6.40 (unch)
CECE : 6.83 (+1.19%)
MKGI : 2.27 (+7.08%)
AUUD : 2.53 (+4.98%)
ARHH : 1.5300 (-4.38%)
DLPN : 12.16 (+1.93%)
IMAC : 1.4700 (+2.80%)
COMS : 1.8200 (+8.98%)
MYO : 12.03 (+0.67%)
MRVFF : 1.0900 (+2.83%)
MINM : 1.8100 (+2.84%)
DTST : 4.55 (-5.41%)
NLSP : 2.54 (-0.39%)
AWH : 3.55 (+1.72%)
ISDR : 26.41 (+1.97%)
BMRA : 4.61 (+2.67%)
ALIM : 4.69 (-1.88%)
LFMD : 7.29 (+0.97%)
ANDA : 9.20 (+3.37%)
BIOL : 0.6753 (+0.96%)
FBIO : 3.34 (+6.03%)
DHX : 4.39 (+3.05%)
MLSS : 1.8500 (+3.93%)
ORGS : 5.08 (+2.83%)
ELYS : 4.68 (+0.43%)
THBRF : 3.6395 (+3.72%)
NMRD : 5.94 (-3.73%)
DXR : 10.64 (-3.97%)
Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100(R) Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. In...

DXR : 10.64 (-3.97%)
Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100(R) (Blood Volume Analyzer) with the United States Department of Veterans Affairs

Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a multi-center clinical trial with two Veterans Affairs Medical Centers to...

DXR : 10.64 (-3.97%)
Newly Published Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-100(R)) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in postural tachycardia...

DXR : 10.64 (-3.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Daxor Corporation is a medical device manufacturing corporation with additional biotech services.

See More

Key Turning Points

3rd Resistance Point 11.76
2nd Resistance Point 11.53
1st Resistance Point 11.09
Last Price 10.64
1st Support Level 10.42
2nd Support Level 10.19
3rd Support Level 9.75

See More

52-Week High 17.58
Fibonacci 61.8% 14.14
Fibonacci 50% 13.08
Fibonacci 38.2% 12.02
Last Price 10.64
52-Week Low 8.58

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar